179072-57-2

Upstream product

• 16758-34-2 1-thiophenyl-β-D-galactopyranoside 
• 922182-99-8 S-phenyl 4,6-O-benzylidene-3-O-(2-naphthylmethyl)-β-D-thiogalactopyranoside 
• 123-76-2 levulinic acid 
• 179072-68-5 phenyl 4,6-O-benzylidene-3-O-(p-methoxybenzyl)-1-thio-β-D-galactopyranoside 
• 179072-63-0 phenyl 3-O-(4-methoxybenzyl)-1-thio-β-D-galactopyranoside 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 179072-69-6 4-Oxo-pentanoic acid (2S,4aR,6S,7R,8S,8aS)-8-(4-methoxy-benzyloxy)-2-phenyl-6-phenylsulfanyl-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yl ester 

Downstream Products

• 179072-60-7 C₆₈H₇₉NO₂₀ 
• 179072-59-4 C₇₃H₈₅NO₂₂ 
• 179072-58-3 C₇₁H₇₃NO₂₁S 

Relevant academic research and scientific papers

Discovery of Oligosaccharide Antigens for Semi-Synthetic Glycoconjugate Vaccine Leads against Streptococcus suis Serotypes 2, 3, 9 and 14**

Streptococcus suis bacteria are one of the most serious health problems for pigs and an emerging zoonotic agent in humans working in the swine industry. S. suis bacteria express capsular polysaccharides (CPS) a major bacterial virulence factor that define the serotypes. Oligosaccharides resembling the CPS of S. suis serotypes 2, 3, 9, and 14 have been synthesized, glycans related to serotypes 2 and 9 were placed on glycan array surfaces to screen blood from infected pigs. Lead antigens for the development of semi-synthetic S. suis serotypes 2 and 9 glycoconjugate veterinary vaccines were identified in this way.

Orthogonal glycosylation strategy in synthesis of extended blood group B determinant

The orthogonal glycosylation strategy was applied for the synthesis of extended blood type B determinant (2) of a novel glycolipid 1. Key features in the synthesis are 1) four monosaccharide units were synthesized as either glycosyl fluoride or thioglycoside to be engaged to the orthogonal glycosylation strategy and 2) all necessary manipulations were completed at the monosaccharide level, therefore, manipulations during the elongation of sugar chain were minimized.